The FDA on September 19, 2024, approved RYBREVANT® with Carboplatin and Pemetrexed for adult patients with locally advanced or metastatic Non-Small Cell Lung Cancer (NSCLC) with Epidermal Growth Factor Receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations whose disease has progressed on or after treatment with an EGFR tyrosine kinase inhibitor. RYBREVANT® is a product of Janssen Biotech, Inc.
Bottom Ad
Advertisement
Subscribe
